Auckland Cancer Society Research Centre seminar: Product profiles and drug discovery Event as iCalendar

25 November 2013

11am - 12pm

Venue: Seminar Room 503-020, Building 503, 85 Park Road, Grafton

Most of what we see in the public domain are the success stories and often these are used to exemplify how to undertake good drug discovery. However, most of what we undertake fails and this rarely sees the light of day. In this talk I will go behind the scenes and use a range of examples of failures within the industry to illustrate the simple things that can and do lead to failure.

As part of this I will discuss product and molecule profiles, what they mean and how they can support good decision making in drug discovery.

Presented by David Middlemiss PhD BSc

David Middlemiss is a Medicinal Chemist by training and has over 45 years’ experience in all aspects of Drug Discovery and Development. He spent his industrial career with Glaxo where he led teams and projects in a variety of disease areas. He was involved in the discovery of the long-acting b2-agonist salmeterol and led the teams that discovered the NK1 antagonist, vofopitant and the H2-antagonist, Zantac.

At GlaxoWellcome David was International Therapeutic Research Director for Cardiovascular Diseases where he had accountability for Drug Discovery from Research through pre-clinical development to ‘Proof of Concept’ studies in humans. At GlaxoSmithKline he briefly served as World-wide Director, Genetics Portfolio where he was accountable for prioritizing the organizations genetics and genomics research projects and aligning them with Drug Discovery and Development.

He now acts as an independent consultant where he advises project and senior management teams on Drug Discovery. He is an author on more than fifty scientific papers, is an inventor on 65 patents and has taken 14 drug candidates into development.

For further information please contact: Julie Spicer. j.spicer